UNSPSC 51401510: Medazepam

This classification denotes a benzodiazepine with the molecular formula C16H15ClN2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P0J3387W3S, chemically known as 2,3-dihydro-7-chloro-1-methyl-5-phenyl-1h-1,4-benzodiazepine but generally known as medazepam, which bears US NIH Compound Identifier 4041. European Medicines Agency schedules Medazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08689MIG.

UNSPSC 51401510 Medazepam is a Commodity code, but the recent state and local procurement activity indexed under it does not align with the code's nominal pharmaceutical scope. Seminole County, Florida posted an IFB for naloxone and drug deactivation systems—emergency-response and harm-reduction supplies—rather than medazepam, a benzodiazepine medication. The mismatch suggests either a data-entry or classification error in the county's tagging of the solicitation rather than authentic market activity under this Commodity code. State and local procurement databases occasionally mis-code opportunities when posting systems allow manual entry without strict taxonomy validation.

The single recent opportunity on record, Seminole County IFB 60459723LAS (response deadline July 26, 2023), sought annual supply of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. Vendors were required to submit bids electronically, include all shipping and delivery costs, obtain E-Verify compliance and drug-free workplace certification, and carry workers' compensation, commercial general liability, and professional liability insurance. The contract term was two years with an optional one-year renewal and included a three-month probationary termination period. The solicitation did not specify set-aside designations. No other recent state or local opportunities under this code are present in the source, and the naloxone procurement, while recent, does not reflect genuine market demand for medazepam at the state and local level.